4.7 Review

Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies

期刊

出版社

MDPI
DOI: 10.3390/ijms24119527

关键词

genome editing; hemoglobinopathies; sickle cell disease; thalassemia; CRISPR/Cas9; base editing; prime editing; hereditary persistence of fetal hemoglobin

向作者/读者索取更多资源

Beta-hemoglobinopathies, the most common genetic disorders globally, can be cured by gene therapy or genome editing approaches. Gene therapy involves introducing therapeutic genes into patients' stem cells, while genome editing targets specific mutations for disease modification. These approaches have shown promising outcomes in increasing transfusion independence and reducing symptoms. Ongoing research on new HbF modulators and long-term follow-up studies are needed for further confirmation.
Beta-hemoglobinopathies are the most common genetic disorders worldwide, caused by a wide spectrum of mutations in the beta-globin locus, and associated with morbidity and early mortality in case of patient non-adherence to supportive treatment. Allogeneic transplantation of hematopoietic stem cells (allo-HSCT) used to be the only curative option, although the indispensable need for an HLA-matched donor markedly restricted its universal application. The evolution of gene therapy approaches made possible the ex vivo delivery of a therapeutic beta- or gamma-globin gene into patient-derived hematopoietic stem cells followed by the transplantation of corrected cells into myeloablated patients, having led to high rates of transfusion independence (thalassemia) or complete resolution of painful crises (sickle cell disease-SCD). Hereditary persistence of fetal hemoglobin (HPFH), a syndrome characterized by increased gamma-globin levels, when co-inherited with beta-thalassemia or SCD, converts hemoglobinopathies to a benign condition with mild clinical phenotype. The rapid development of precise genome editing tools (ZFN, TALENs, CRISPR/Cas9) over the last decade has allowed the targeted introduction of mutations, resulting in disease-modifying outcomes. In this context, genome editing tools have successfully been used for the introduction of HPFH-like mutations both in HBG1/HBG2 promoters or/and in the erythroid enhancer of BCL11A to increase HbF expression as an alternative curative approach for beta-hemoglobinopathies. The current investigation of new HbF modulators, such as ZBTB7A, KLF-1, SOX6, and ZNF410, further expands the range of possible genome editing targets. Importantly, genome editing approaches have recently reached clinical translation in trials investigating HbF reactivation in both SCD and thalassemic patients. Showing promising outcomes, these approaches are yet to be confirmed in long-term follow-up studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据